NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Medical Instruments & Supplies · USD

STAAR Surgical Company (STAA) Stock Analysis

STAAR Surgical Company (STAA) is a Medical Instruments & Supplies stock listed on NASDAQ and quoted in US Dollar.

STAA

$23.47

−$0.11 (−0.47%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare STAA with… →

STAA Key Statistics

As of Sep 4, 2026
Trading
Open
$23.47
Previous Close
$23.58
Day's Range
23.40–24.37
52-Week Range
15.59–35.87
Volume
1.97M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.22
Valuation
Market Cap
$1.18B
P/E Ratio
293.38
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
22.93
PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
0.76
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
3.47
EPS (ttm)Profit attributable to each share over the last twelve months.
0.08
Financials (FY)
Revenue (FY)
$239.44M−23.72%
Net Income (FY)
−$80.45M
Profit marginThe share of revenue left as profit after all costs and taxes.
1.13%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
50.14M
1-Year Return
−15.51%
Dividend and dates
Earnings Date
November 11, 2026estimated
Avg Volume
844.27K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

STAA Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+1.65%
2025−4.94%
2024−22.17%
2023−35.70%
2022−46.83%
2021+15.25%
2020+125.25%
2019+10.22%
2018+105.87%
2017+42.86%
2016 (partial year)+29.94%

As of September 4, 2026.

STAA Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$239.44M−$80.45M−33.6%
2024$313.90M−$20.21M−6.4%
2023$322.42M$21.35M6.6%
2022$284.39M$39.67M13.9%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$239.44M$182.42M−$45.95M−$80.45M−33.6%
2024$313.90M$239.58M−$12.61M−$20.21M−6.4%
2023$322.42M$252.65M$28.10M$21.35M6.6%
2022$284.39M$223.38M$43.80M$39.67M13.9%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

STAA Valuation vs Medical Instruments & Supplies Median

Median of 55 stocks
MetricSTAAMedical Instruments & Supplies medianvs median
P/E293.3835.618.2x the median
P/S ratio3.473.179% above
Profit margin1.13%0.85%0.3 pts above

Medians across 55 Medical Instruments & Supplies stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 8 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

STAAR Surgical Company (STAA) is capitalised at $1.18B on the latest close. It is classified in the Medical Instruments & Supplies industry, within the Healthcare sector. Headcount on file is 921.

The 52-week range on file runs from $15.59 to $35.87. STAA last closed at $23.47 on September 4, 2026. That is −$0.11 (−0.47%) against the previous close. The latest close sits 50.55% above that 52-week low.

Financial Health

In fiscal 2025, STAAR Surgical Company reported revenue of $239.44M. That is −23.72% against the prior fiscal year, when revenue was $313.90M. The same year closed with a net loss of $80.45M. Profit margin runs at 1.13%. That is 0.3 percentage points above the Medical Instruments & Supplies median of 0.85%. Earnings per share on a trailing basis come to 0.08.

Across the 4 fiscal years on file, revenue moves from $284.39M in 2022 to $239.44M in 2025. Of those 4 years, 2 report positive net income.

Valuation Assessment

The trailing P/E ratio stands at 293.38. That is 8.2 times the Medical Instruments & Supplies median of 35.61. The forward P/E on file is 22.93. The PEG ratio, which sets the P/E against expected earnings growth, reads 0.76. Measured against sales, the shares trade at 3.47 times revenue. On price-to-sales that is 9.23% above the Medical Instruments & Supplies median of 3.17. The medians here are taken across 55 Medical Instruments & Supplies companies that report the metric.

The reported beta is 1.22. Annualized volatility over the trailing 10 years is 58.23%. The trailing one-year price return is −15.51%. Measured over 10 years, that is +10.11% a year compounded.

Growth & Income

No dividend is on file for STAA.

Across the complete calendar years on file, 2020 returned +125.25% and 2022 returned −46.83%. Of the 9 complete calendar years on file, 5 finished higher. 2026 is still running; the price is +1.65% year to date.

Peer Comparison

STAAR Surgical Company (STAA) operates in the Medical Instruments & Supplies industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
STAAR Surgical Company STAA $1.18B 293.4
Intuitive Surgical, Inc. ISRG $131.38B 42.4
Becton, Dickinson and Company BDX $50.32B 32.0
Medline Inc. MDLN $49.23B 45.7

The Medical Instruments & Supplies industry average P/E ratio is 35.6x. STAAR Surgical Company trades at a P/E of 293.4.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Medical Instruments & Supplies Stocks

ISRG

Intuitive Surgical, Inc.

$131.38B

 BDX

Becton, Dickinson and Company

$50.32B

 MDLN

Medline Inc.

$49.23B

 ALC

Alcon Inc.

$34.08B

 RMD

ResMed Inc.

$32.94B

 WST

West Pharmaceutical Services, Inc.

$23.93B
View all Medical Instruments & Supplies stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About STAAR Surgical Company

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, and sells phakic implantable lenses for the eye and accessory delivery systems to deliver the lenses into the eye. The company offers implantable collamer lens product family (ICLs) comprising EVO ICL, EVO+ ICL, EVO Visian ICL, and EVO Viva ICL for use in refractive surgery for the treatment of visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia. It serves health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as ophthalmologists. The company sells its products directly through its sales representatives in Japan, the United States, Germany, Spain, Singapore, Canada, and the United Kingdom, as well as through representatives and independent distributors in China, Korea, India, France, Benelux, Italy, and internationally. STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California.

Visit website →